BACKGROUND: Cohort studies have described the short-term effectiveness and safety of vedolizumab in treating patients with Crohn's disease (CD) and ulcerative colitis (UC), but data beyond 1 year are lacking. AIM: To assess the effectiveness and safety of vedolizumab after 162 weeks in patients with UC and CD. METHODS: Between June and December 2014, 294 patients including 173 patients with CD and 121 with UC were treated with vedolizumab induction therapy. Among them, 149 continued to be treated with vedolizumab beyond week 54 (78 patients with CD and 71 with UC). Disease activity was assessed using the Harvey-Bradshaw Index for CD and the partial Mayo Clinic score for UC. The primary outcome was steroid-free clinical remission at week 162, computed for the whole population included at week 0. RESULTS: Steroid-free clinical remission rates at week 162 were 19.9% and 36.1% in patients with CD and UC respectively. Vedolizumab dose optimisation to 300 mg every 4 weeks instead of 300 mg every 8 weeks was at investigator's discretion and occurred in 58.7% and 52.1% of patients with CD and UC respectively. The 1-, 2- and 3-year persistence rates of vedolizumab were 48.5%, 31.4% and 26.3% respectively, in patients with CD and 61.0%, 49.9% and 42.9% respectively, in patients with UC. No new safety signal was identified. CONCLUSION: Vedolizumab is able to maintain steroid-free clinical remission in patients with UC and CD up to week 162. Loss of response resulting in discontinuation of vedolizumab occurred in 10% of patients per year.
BACKGROUND: Cohort studies have described the short-term effectiveness and safety of vedolizumab in treating patients with Crohn's disease (CD) and ulcerative colitis (UC), but data beyond 1 year are lacking. AIM: To assess the effectiveness and safety of vedolizumab after 162 weeks in patients with UC and CD. METHODS: Between June and December 2014, 294 patients including 173 patients with CD and 121 with UC were treated with vedolizumab induction therapy. Among them, 149 continued to be treated with vedolizumab beyond week 54 (78 patients with CD and 71 with UC). Disease activity was assessed using the Harvey-Bradshaw Index for CD and the partial Mayo Clinic score for UC. The primary outcome was steroid-free clinical remission at week 162, computed for the whole population included at week 0. RESULTS:Steroid-free clinical remission rates at week 162 were 19.9% and 36.1% in patients with CD and UC respectively. Vedolizumab dose optimisation to 300 mg every 4 weeks instead of 300 mg every 8 weeks was at investigator's discretion and occurred in 58.7% and 52.1% of patients with CD and UC respectively. The 1-, 2- and 3-year persistence rates of vedolizumab were 48.5%, 31.4% and 26.3% respectively, in patients with CD and 61.0%, 49.9% and 42.9% respectively, in patients with UC. No new safety signal was identified. CONCLUSION:Vedolizumab is able to maintain steroid-free clinical remission in patients with UC and CD up to week 162. Loss of response resulting in discontinuation of vedolizumab occurred in 10% of patients per year.
Authors: Vince B C Biemans; C Janneke van der Woude; Gerard Dijkstra; Andrea E van der Meulen-de Jong; Mark Löwenberg; Nanne K de Boer; Bas Oldenburg; Nidhi Srivastava; Jeroen M Jansen; Alexander G L Bodelier; Rachel L West; Annemarie C de Vries; Jeoffrey J L Haans; Dirk de Jong; Frank Hoentjen; Marieke J Pierik Journal: Aliment Pharmacol Ther Date: 2020-05-22 Impact factor: 8.171
Authors: Patrizio Scarozza; Irene Marafini; Federica Laudisi; Edoardo Troncone; Heike Schmitt; Marco Vincenzo Lenti; Stefania Costa; Irene Rocchetti; Elena De Cristofaro; Silvia Salvatori; Ludovica Frezzati; Antonio Di Sabatino; Raja Atreya; Markus F Neurath; Emma Calabrese; Giovanni Monteleone Journal: J Clin Med Date: 2020-02-01 Impact factor: 4.241
Authors: Vince B C Biemans; C Janneke van der Woude; Gerard Dijkstra; Andrea E van der Meulen-de Jong; Bas Oldenburg; Nanne K de Boer; Mark Löwenberg; Nidhi Srivastava; Alexander G L Bodelier; Rachel L West; Jeroen M Jansen; Annemarie C de Vries; Jeoffrey J L Haans; Dirk J de Jong; Marie J Pierik; Frank Hoentjen Journal: Clin Pharmacol Ther Date: 2019-12-11 Impact factor: 6.875
Authors: Vince B C Biemans; Edo Savelkoul; Ruben Y Gabriëls; Melek Simsek; Gerard Dijkstra; Marieke J Pierik; Rachel L West; Nanne K H de Boer; Frank Hoentjen Journal: Aliment Pharmacol Ther Date: 2020-04-27 Impact factor: 8.171
Authors: Samba Siva Reddy Pulusu; Ashish Srinivasan; Krupa Krishnaprasad; Daniel Cheng; Jakob Begun; Charlotte Keung; Daniel Van Langenberg; Lena Thin; Tamara Mogilevski; Peter De Cruz; Graham Radford-Smith; Emma Flanagan; Sally Bell; Soleiman Kashkooli; Miles Sparrow; Simon Ghaly; Peter Bampton; Elise Sawyer; Susan Connor; Quart-Ul-Ain Rizvi; Jane M Andrews; Gillian Mahy; Paola Chivers; Simon Travis; Ian Craig Lawrance Journal: World J Gastroenterol Date: 2020-08-14 Impact factor: 5.742
Authors: Orla Mader; Pascal Juillerat; Luc Biedermann; Pierre Michetti; Petr Hruz; Valerie Pittet; Gerhard Rogler; Nadine Zahnd-Straumann; Frank Seibold Journal: United European Gastroenterol J Date: 2021-02-26 Impact factor: 4.623